Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 10, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
- Shareholding Decrease: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,560,178 to 18,473,127.
- Transaction Date: The movement occurred on February 5, 2004.
- Average Price: The shares were transacted at an average price of $44.97.
- Directors' Interest: Directors Dr. J.P. Garnier and Dr. T. Yamada are noted as potentially interested in the shares held in the fund, consistent with other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a routine disclosure of fund movements affecting director interests.
Key Facts for Investor Verification
- Verify the impact of the 87,051 share decrease in the US Retirement Savings Plan on total director holdings.
- Confirm the average transaction price of $44.97 against market prices on February 5, 2004.
- Review the specific terms of the discretionary fund to understand the extent of potential interest for Directors Garnier and Yamada.